Capricor Therapeutics’ (CAPR) Buy Rating Reaffirmed at HC Wainwright
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $77.00 price objective on the biotechnology company’s stock. Separately, Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and […]
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $77.00 price objective on the biotechnology company’s stock. Separately, Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and […]
